US 11,951,154 B2
Compositions and methods for cell delivery
Laura Gabriela Lande, Chestnut Hill, MA (US); and David Arthur Berry, Newton, MA (US)
Assigned to FLAGSHIP PIONEERING INNOVATIONS V, INC., Cambridge, MA (US)
Filed by Flagship Pioneering Innovations V, Inc., Cambridge, MA (US)
Filed on Jun. 8, 2022, as Appl. No. 17/835,659.
Application 17/835,659 is a continuation of application No. 16/346,684, granted, now 11,382,950, previously published as PCT/US2017/059610, filed on Nov. 1, 2017.
Claims priority of provisional application 62/416,378, filed on Nov. 2, 2016.
Claims priority of provisional application 62/416,372, filed on Nov. 2, 2016.
Claims priority of provisional application 62/416,367, filed on Nov. 2, 2016.
Prior Publication US 2023/0024896 A1, Jan. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/00 (2006.01); A61K 38/16 (2006.01); A61K 47/64 (2017.01); A61K 47/65 (2017.01); C07K 7/08 (2006.01); C07K 9/00 (2006.01)
CPC A61K 38/16 (2013.01) [A61K 47/64 (2017.08); A61K 47/65 (2017.08); C07K 7/08 (2013.01); C07K 9/00 (2013.01)] 19 Claims
 
1. A method of delivering a therapeutic comprising: administering a composition to a subject, the composition comprising: a polypeptide comprising at least one sequence of ABX″C, wherein A is selected from a hydrophobic amino acid or an amide containing backbone, with a nucleic acid side chain; B and C may be the same or different, and are independently selected from arginine, asparagine, glutamine, lysine, and analogs thereof; X is an amide containing backbone, with a nucleic acid side chain; and n is an integer from 1 to 4; and at least one heterologous moiety, wherein the heterologous moiety is the therapeutic, and wherein the composition increases intracellular delivery of the therapeutic as compared to the therapeutic alone.